50 related articles for article (PubMed ID: 1491696)
1. Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.
Fan P; Cunliffe HE; Griffith OL; Agboke FA; Ramos P; Gray JW; Jordan VC
Eur J Cancer; 2014 Nov; 50(16):2877-86. PubMed ID: 25212499
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.
Chakraborty S; Biswas PK
J Mol Model; 2014 Aug; 20(8):2338. PubMed ID: 25060147
[TBL] [Abstract][Full Text] [Related]
3. A Novel Metastatic Estrogen Receptor-Expressing Breast Cancer Model with Antiestrogen Responsiveness.
Langsten KL; Shi L; Wilson AS; Lumia S; Westwood B; Skeen AM; Xie MT; Surratt VE; Turner J; Langefeld CD; Singh R; Cook KL; Kerr BA
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136319
[TBL] [Abstract][Full Text] [Related]
4. Computational investigations of the binding mechanism of novel benzophenone imine inhibitors for the treatment of breast cancer.
Shtaiwi A; Adnan R; Khairuddean M; Khan SU
RSC Adv; 2019 Oct; 9(61):35401-35416. PubMed ID: 35541022
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and computational insights of flavone derivatives as potential estrogen receptor alpha (ER-α) antagonist.
Fegade BS; Jadhav SB; Chaudhari SY; T Tandale D; Shantaram Uttekar P; Tabrez S; Khan MS; Zaidi SK; Mukerjee N; Ghosh A
J Biomol Struct Dyn; 2023 Nov; ():1-10. PubMed ID: 38006310
[TBL] [Abstract][Full Text] [Related]
6. Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.
Jordan VC
Breast Cancer Res Treat; 2021 Nov; 190(1):19-38. PubMed ID: 34398352
[TBL] [Abstract][Full Text] [Related]
7. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.
Katzenellenbogen JA; Mayne CG; Katzenellenbogen BS; Greene GL; Chandarlapaty S
Nat Rev Cancer; 2018 Jun; 18(6):377-388. PubMed ID: 29662238
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen resistance in breast cancer.
Chang M
Biomol Ther (Seoul); 2012 May; 20(3):256-67. PubMed ID: 24130921
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.
Balaburski GM; Dardes RC; Johnson M; Haddad B; Zhu F; Ross EA; Sengupta S; Klein-Szanto A; Liu H; Lee ES; Kim H; Jordan VC
Int J Oncol; 2010 Aug; 37(2):387-98. PubMed ID: 20596666
[TBL] [Abstract][Full Text] [Related]
10. Effects of adiponectin on breast cancer cell growth and signaling.
Grossmann ME; Nkhata KJ; Mizuno NK; Ray A; Cleary MP
Br J Cancer; 2008 Jan; 98(2):370-9. PubMed ID: 18182989
[TBL] [Abstract][Full Text] [Related]
11. Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line.
Pink JJ; Fritsch M; Bilimoria MM; Assikis VJ; Jordan VC
Br J Cancer; 1997; 75(1):17-27. PubMed ID: 9000593
[TBL] [Abstract][Full Text] [Related]
12. Androgen signal transduction and prostatic carcinoma.
Klocker H; Culig Z; Kaspar F; Hobisch A; Eberle J; Reissigl A; Bartsch G
World J Urol; 1994; 12(2):99-103. PubMed ID: 8087144
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of antiestrogen action in breast cancer.
Jordan VC
Breast Cancer Res Treat; 1994; 31(1):41-52. PubMed ID: 7981455
[TBL] [Abstract][Full Text] [Related]
14. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.
Wolf DM; Jordan VC
Breast Cancer Res Treat; 1994; 31(1):129-38. PubMed ID: 7981453
[TBL] [Abstract][Full Text] [Related]
15. William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.
Wolf DM; Jordan VC
Breast Cancer Res Treat; 1993; 27(1-2):27-40. PubMed ID: 7505127
[TBL] [Abstract][Full Text] [Related]
16. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
[TBL] [Abstract][Full Text] [Related]
17. A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens.
Jiang SY; Parker CJ; Jordan VC
Breast Cancer Res Treat; 1993; 26(2):139-47. PubMed ID: 8219251
[TBL] [Abstract][Full Text] [Related]
18. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
